Please use this identifier to cite or link to this item: http://hdl.handle.net/2067/48043
Title: CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype
Authors: Filippi, Silvia
Paccosi, Elena
Balzerano, Alessio
Ferretti, Margherita
Poli, Giulia
Taborri, Juri 
Brancorsini, Stefano
Proietti De Santis, L. 
Journal: CANCERS 
Issue Date: 2022
Abstract: 
Breast cancer (BC), the most frequent malignancy in woman, shows a high rate of cancer recurrence and resistance to treatment, particularly in Triple-Negative Breast Cancer (TNBC) subtype. Starting from the observation that different subtypes of BC cells, including the TNBC one, display an increased expression of Cockayne Syndrome group A (CSA) protein, which is involved in multiple functions such as DNA repair, transcription and in conferring cell robustness when it is up-regulated, we demonstrated that CSA ablation by AntiSense Oligonucleotides (ASOs) drastically impairs tumorigenicity of BC cells by hampering their survival and proliferative capabilities without affecting normal breast cells. Suppression of CSA does result in lowering the IC50 value of Oxaliplatin and Paclitaxel, two commonly used chemotherapeutic agents in breast cancer treatment, allowing the use of a very low dose of chemotherapeutic that is non-toxic to the normal breast cell line. Finally, CSA ablation restores drug sensitivity in oxaliplatin-resistant cells. Based on these findings, we can conclude that CSA may be a very attractive target for the development of new specific anticancer therapies.
URI: http://hdl.handle.net/2067/48043
ISSN: 2072-6694
DOI: https://doi.org/10.3390/cancers14071687
Rights: Attribution 4.0 International
Appears in Collections:A1. Articolo in rivista

Files in This Item:
File Description SizeFormat
cancers-14-01687-v2.pdf1.98 MBAdobe PDFView/Open
Show full item record

Page view(s)

52
Last Week
0
Last month
0
checked on Mar 27, 2024

Download(s)

6
checked on Mar 27, 2024

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons